|
|
High Throughput Genomics, Inc., (HTG), is a provider of transcriptomic technology and services. HTG’s technology opens a new era of drug discovery and allows companies to identify new drug compounds, quickly eliminate less promising compounds and bring new drugs to market faster. HTG is the first company to commercialize this technology. HTG is online at www.htgenomics.com. IndustryThe genomic revolution has flooded the pharmaceutical industry with an exponential increase in the number of potential drug targets. As a result, the cost and effort of discovering new drugs using existing technologies has risen and is expected to explode in the next few years. Pharmaceutical companies are looking for solutions that help them hone in on the most promising targets, allow simultaneous pursuit of multiple targets, identify drug candidates that are likely to be well tolerated and safe for patients, and enable drug discovery at the gene level.HTG’s platform provides life sciences researchers with critical information on active genes, or RNA, making it the first to bridge the gap between genomics and proteomics. HTG’s technology is uniquely able to analyze the interplay of multiple active genes, in addition to measuring DNA expression and assessing protein function, providing customers with accurate, reproducible data on how potential new drugs act in a cell or organism. Business Challenge- Researchers and scientists are often jaded by biotech companies’ claims to accelerate drug discovery and bring drugs to market faster. Many of these companies are unable to substantiate these claims or produce real-world examples. HTG needed to rise above this discussion and emerge as a technology provider that solves real research problems in drug discovery.
- Distinguish HTG’s technology from the established method, real-time PCR.
- Researchers are aware of the potential of gene-to-drug discovery, but, until now, they have not had the ability to measure RNA accurately and easily. HTG is the first to provide scientists with products and services and to enable pharmaceutical companies to close the gene-to-drug discovery gap. HTG needed to prove this.
Schwartz PR Strategy- Raise awareness among the company’s target customers—VPs of research, chief scientific officers, scientists and program directors at pharmaceutical and biopharmaceutical companies—about HTG’s technology. Help them understand how, using HTG’s technology, they can support their drug discovery programs by making new use of existing drug targets or discover novel pathways controlled by the interplay of several genes.
- Develop strategic messages that establish and position HTG as the market leader in transcriptomics and the first company to truly commercialize technology to study the transcriptome.
- Execute a bylined article placement campaign to promote the utility of technology that looks at gene expression.
- Secure speaking engagements for HTG executives and customers to present data on novel results achieved using HTG’s technology.
- Increase awareness of the company in the life sciences and biotech venture capital community. Focus on VCs making early-stage investments.
- Help stimulate new sales leads and compress the sales cycle as potential customers gain a better understanding of the benefits of HTG’s technology and services through consistent public relations coverage in life sciences, pharmaceutical and biotech trade media.
- Raise the visibility of HTG in the Arizona media.
- Establish key HTG executives as industry experts on genomics, proteomics, transcriptomics, gene expression and other industry topics in pharmaceutical and scientific publications.
Results- Schwartz has positioned HTG’s management team as industry experts and communicated the benefits of HTG’s platform through a new product announcement and technology agreement. This has resulted in interviews, published executive Q&As and HTG’s inclusion in features in such publications as Science, Genetic Engineering News, BioTechniques, Drug Discovery and Development, In Vivo, Pharmaceutical Technology, Genomics and Proteomics, R&D Magazine and The Scientist.
- Schwartz has orchestrated four company news announcements (office expansion, CFO appointment, new board member, grant award) as the proxies to secure feature, standalone profiles for HTG in a variety of local media outlets, including The Arizona Republic, The Phoenix Business Journal, Inside Tucson Business, Tucson Citizen, Arizona Business, Arizona Daily Star and bizAZ.
- Schwartz has placed numerous bylined articles on behalf of HTG and played a critical role in the development and positioning of each placement. This has resulted in coverage in American Biotechnology Laboratory, the Cambridge Healthcare Institute newsletter, PharmaGenomics, PreClinica, Modern Drug Discovery and Drug Discovery World.
- To date, Schwartz has secured nine conference speaking engagements for HTG. Venues include Proteins to Profits, Cambridge Healthtech Institute’s Fifth Annual Drug Discovery Conference, Profiling PCR and Beyond, BioPhex, Business of Biotech Symposium and Expo, Chips to Hits, Genomics on Target: Functional Genomics and Target Validation, Lab Automation and ScreenTech World Summit.
|
|
